dronabinol has been researched along with MS (Multiple Sclerosis) in 196 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.53) | 18.7374 |
| 1990's | 4 (2.04) | 18.2507 |
| 2000's | 40 (20.41) | 29.6817 |
| 2010's | 118 (60.20) | 24.3611 |
| 2020's | 31 (15.82) | 2.80 |
| Authors | Studies |
|---|---|
| Conte, A; Vila Silván, C | 1 |
| Chan, A; Silván, CV | 1 |
| Borrelli, F; Cinquini, M; Dwan, K; Filippini, G; Minozzi, S | 1 |
| Adjamian, P; Bagul, M; Carod-Artal, FJ; Gasperini, C; Vila Silván, C | 1 |
| Chisari, CG; Fernández, Ó; Ferrer-Picón, E; Hernández Vicente, F; Patti, F; Sarroca, J; Vila Silván, C | 1 |
| Dykukha, I; Essner, U; Penner, IK; Raithel, LM; Schreiber, H | 1 |
| Alasvand, M; Bozorgi, H; Di Ciano, P; Ghasemi-Pirbaluti, M; Motaghi, E; Rashidi, M | 1 |
| Benedetti, MD; Calabrese, M; Cardobi, N; Gajofatto, A; Gobbin, F; Turatti, M | 1 |
| Berwaerts, J; Checketts, D; Chinnapongse, R; Javaid, S; Klineova, S; Lublin, F; Nicholas, J; Steinerman, JR | 1 |
| Barré, T; Carrieri, P; Marcellin, F; Protopopescu, C; Radoszycki, L; Ramier, C; Roux, P; Santos, M; Testa, D | 1 |
| Bunduc, S; Csupor, D; Fehérvári, P; Gergő, D; Hegyi, P; Horváth, IL; Kleiner, D; Lugosi, K | 1 |
| Al-Ghezi, ZZ; Miranda, K; Nagarkatti, M; Nagarkatti, PS | 1 |
| Boles Ponto, LL; Kamholz, J; Kindred, JH; Rudroff, T; Workman, CD | 1 |
| Hudnall, MT; Nadler, RB; Pham, MN | 1 |
| Essner, U; Henze, T; Meuth, SG; Trompke, C; Vila Silván, C | 1 |
| Brescia Morra, V; Carotenuto, A; Costabile, T; De Angelis, M; De Lucia, M; Falco, F; Lanzillo, R; Moccia, M; Petruzzo, M; Russo, CV; Saccà, F | 1 |
| Cortesi, PA; Cozzolino, P; Mantovani, LG; Patti, F | 1 |
| Chang-Douglass, S; Mulvihill, C; Pilling, S | 1 |
| Benedetti, MD; Berra, E; Bianco, A; Bruno Bossio, R; Buttari, F; Castelli, L; Cavalla, P; Cerqua, R; Chisari, CG; Costantino, G; Gasperini, C; Guareschi, A; Ippolito, D; Lanzillo, R; Maniscalco, GT; Matta, M; Paolicelli, D; Patti, F; Petrucci, L; Pontecorvo, S; Righini, I; Russo, M; Saccà, F; Salamone, G; Signoriello, E; Solaro, C; Spinicci, G; Spitaleri, D; Tavazzi, E; Trotta, M; Zaffaroni, M; Zappia, M | 1 |
| Balletta, T; Bramanti, P; Calabrò, RS; Ciurleo, R; D'Aleo, G; Destro, M; La Via, C; Naro, A; Rifici, C; Russo, M; Sessa, E | 1 |
| Carra, A; Fragoso, YD; Macias, MA | 1 |
| Alessandria, G; Bandini, F; Capello, E; Infante, MT; Meli, R; Vestito, L | 1 |
| Annunziata, P; Bergamaschi, R; Bianco, A; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Capello, E; Castelli, L; Cavalla, P; Centonze, D; Chisari, CG; Costantino, G; Cottone, S; Danni, MC; Esposito, F; Gajofatto, A; Gasperini, C; Guareschi, A; Lanzillo, R; Lus, G; Maniscalco, GT; Matta, M; Paolicelli, D; Patti, F; Petrucci, L; Pontecorvo, S; Righini, I; Rovaris, M; Sessa, E; Solaro, C; Spinicci, G; Spitaleri, D; Valentino, P; Zaffaroni, M; Zappia, M | 1 |
| Jones, É; Vlachou, S | 1 |
| Ab, O; Bs, R; F, S; Hb, S; K, L; Ps, S; R, T; S, G | 1 |
| Bhattacharyya, S; McGoohan, KL; Velayudhan, L | 1 |
| Paul, F; Silván, CV | 1 |
| Bosco, A; Bratina, A; Dinoto, A; Manganotti, P; Mazzon, G; Morelli, ME; Pasquin, F; Sartori, A; Stragapede, L | 1 |
| Prieto González, JM; Vila Silván, C | 1 |
| De Blasiis, P; Fullin, A; Lus, G; Melone, MAB; Sampaolo, S; Sansone, M; Siani, MF; Signoriello, E | 1 |
| Contreras Bolaños, LA; Guevara Moriones, N; Mejía Piñeros, AL; Moreno Vergara, AF; Rodríguez Mesa, XM; Santander González, SP | 1 |
| D'haeseleer, M; D'hooghe, M; Delvaux, V; Guillaume, D; Laureys, G; Nagels, G; Popescu, V; Van Pesch, V; Vanderdonckt, P; Willekens, B | 1 |
| Bergamaschi, R; Bonavita, S; Bossio, RB; Brescia Morra, V; Castelli, L; Cavalla, P; Centonze, D; Comi, G; Costantino, G; Cottone, S; Danni, MC; Francia, A; Gajofatto, A; Gasperini, C; Granata, A; Maniscalco, GT; Matta, M; Messina, S; Mirabella, M; Paolicelli, D; Patti, F; Pedà, G; Petrucci, L; Righini, I; Rovaris, M; Sessa, E; Signoriello, E; Solaro, C; Spinicci, G; Spitaleri, D; Zaffaroni, M; Zappia, M | 1 |
| Aponte, R; Bruzzese, D; Chiariello, F; Florio, C; Guarcello, G; Maniscalco, GT; Manzo, V; Moreggia, O; Napolitano, M | 1 |
| Bramanti, P; Giacoppo, S; Mazzon, E | 1 |
| Häuser, W; Krcevski-Skvarc, N; Wells, C | 1 |
| Izquierdo, G | 1 |
| Linker, R | 1 |
| Bramanti, A; Bramanti, P; Calabrò, RS; Ciurleo, R; Dattola, V; De Luca, R; Logiudice, AL; Naro, A; Russo, M; Sessa, E | 1 |
| Buckley, N; Degenhardt, L; Farrell, M; Germanos, R; Hall, W; Nielsen, S; Pollard, J; Weier, M | 1 |
| Benigni, F; Clarelli, F; Comi, G; Esposito, F; Ferrè, L; Martinelli Boneschi, F; Martinelli, V; Mascia, E; Osiceanu, AM; Sorosina, M; Unal, NT | 1 |
| Castelli, L; Pozzilli, C; Prosperini, L | 1 |
| Constantinescu, CS; Gershkovich, P | 1 |
| Cantello, R; Danni, MC; Lus, G; Rini, A; Sarchielli, P; Signoriello, E; Tassinari, T | 1 |
| Celius, EG; Vila, C | 1 |
| Akmaz, B; Essner, U; Lentschat, A; Marinelli, M; Markovà, J; Trompke, C; Vila, C | 1 |
| Mallada Frechín, J | 1 |
| Cameron, M; Rice, J | 1 |
| Arroyo González, R | 1 |
| Ziemssen, T | 1 |
| Marková, J | 1 |
| Patti, F | 2 |
| Arnold, JC; Banister, SD; Connor, M; Glass, M; McGregor, IS | 1 |
| Al-Ghezi, ZZ; Alghetaa, H; Busbee, PB; Nagarkatti, M; Nagarkatti, PS | 1 |
| Bianco, A; Castelli, L; Centonze, D; Cortese, A; Crisafulli, SG; De Giglio, L; Galgani, S; Grimaldi, AE; Haggiag, S; Marfia, G; Mirabella, M; Monteleone, F; Pozzilli, C; Prosperini, L | 1 |
| Florek, E; Piekoszewski, W; Tkaczyk, M | 1 |
| Klaschik, E; Nauck, F | 1 |
| Constantinescu, CS; Tanasescu, R | 1 |
| Boscá Blasco, I; Casanova-Estruch, B; Escutia Roig, M; Gil Gómez, I; Lorente Fernández, L; Monte Boquet, E; Pérez-Miralles, F; Poveda Andrés, JL | 1 |
| Amato, MP; Koehler, J; Lycke, J; Oreja-Guevara, C | 1 |
| Feneberg, W; Koehler, J; Meier, M; Pöllmann, W | 1 |
| Pozzilli, C | 1 |
| Rekand, T | 1 |
| Koehler, J | 1 |
| Flachenecker, P; Henze, T; Zettl, UK | 2 |
| Erbe, B | 1 |
| McKeage, K; Scott, LJ; Syed, YY | 1 |
| Allsop, DJ; Copeland, J; Fu, S; Lewis, J; Molnar, A | 1 |
| Benyamina, A; Reynaud, M | 1 |
| Brunt, TM; Höner-Snoeken, K; Niesink, RJ; van de Velde, MJ; van Genugten, M | 1 |
| Sedgwick, P | 1 |
| Essner, U; Freidel, M; Lang, M; Prechtl, A; Schreiber, H; Tiel-Wilck, K | 1 |
| Arie, S; Mahony, C | 1 |
| Arroyo, R; Dechant, KL; Vila, C | 1 |
| Centonze, D | 1 |
| Fernández, O | 3 |
| Celius, EG; Donzé, C; Izquierdo, G; Patti, F; Pöhlau, D; Trojano, M | 1 |
| Garcia-Merino, A; Moreno Torres, I; Sanchez, AJ | 1 |
| Colombo, C; Mosconi, P | 1 |
| Batt, S | 1 |
| Basinski, H; Jensen, HB; Stenager, E | 1 |
| Centonze, D; Di Marzo, V | 1 |
| Kramer, JL | 1 |
| Bramanti, P; Calabrò, RS; D'Aleo, G; De Luca, R; Leo, A; Naro, A; Quartarone, A; Rifici, C; Russo, M; Sessa, E | 1 |
| Cimas-Hernando, I; Lorenzo-González, JR; Pato-Pato, A; Rodríguez-Constenla, I | 1 |
| Ruiz, L; Slof, J; Vila, C | 1 |
| Lebrun, C; Vermersch, P | 1 |
| Carrillo-Salinas, FJ; de Lago, E; Feliú, A; Fernández-Ruiz, J; Guaza, C; Mecha, M; Moreno-Martet, M | 1 |
| Bramanti, P; Calabrò, RS; D'Aleo, G; Rifici, C; Russo, M; Sessa, E | 1 |
| Dechant, KL; Meuth, SG; Vila, C | 1 |
| Cocco, E; Coghe, G; Corona, F; Fenu, G; Frau, J; Lorefice, L; Mamusa, E; Marrosu, MG; Massa, R; Massole, S; Musu, L; Pau, M; Spinicci, G | 1 |
| Cressey, D | 1 |
| Pain, S | 1 |
| Colombo, B; Comi, G; Esposito, F; Ferrè, L; Keller Sarmiento, IJ; Leocani, L; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Nuara, A; Pavan, G; Radaelli, M; Rodegher, M | 1 |
| Bazinski, H; Jensen, HB; Stenager, E | 1 |
| Trojano, M; Vila, C | 1 |
| D'Onghia, M; Di Lecce, V; Direnzo, V; Iaffaldano, A; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S | 1 |
| Trojano, M | 3 |
| Vermersch, P | 2 |
| Broughton, J; Gras, A | 1 |
| Bramanti, P; Calabrò, RS; D'Aleo, G; Leo, A; Naro, A; Russo, M; Sessa, E | 1 |
| Abbruzzese, G; Bandini, F; Canneva, S; Capello, E; Colombano, F; Currà, A; Fattapposta, F; Marinelli, L; Mori, L; Trompetto, C | 1 |
| Fu, S; Molnar, A | 1 |
| Barbera, N; Indorato, F; Ledda, C; Liberto, A; Romano, G | 1 |
| Álvarez-Ossorio, L; Haupts, M; Jonas, A; Vila, C; Witte, K | 1 |
| Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M | 1 |
| Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P | 1 |
| Bramanti, P; Calabrò, RS; De Luca, R; Naro, A; Rifici, C; Russo, M; Sessa, E; Torrisi, M | 1 |
| Brunetti, A; Carotenuto, A; Cerillo, I; Cocozza, S; Inglese, M; Iodice, R; Manganelli, F; Orefice, G; Petracca, M; Saiote, C; Tedeschi, E | 1 |
| Brescia Morra, V; Carotenuto, A; Florio, EB; Lanzillo, R; Massarelli, M; Pane, C; Saccà, F | 1 |
| Trojano, M; Vermersch, P | 1 |
| Deotto, L; Donato, F; Erro, R; Moretto, G; Squintani, G; Teatini, F; Turri, M | 1 |
| Filli, L; Ghezzi, A; Landete, L; Lycke, J; Mekies, C; Solaro, C | 1 |
| Flachenecker, P | 2 |
| Ghezzi, A | 1 |
| Keating, GM | 1 |
| Lenk, R; Likar, R | 1 |
| Bereza, B; Desjardins, O; Einarson, TR; Iskedjian, M; Jaszewski, B; Piwko, C | 1 |
| Bari, M; Battistini, L; Bernardi, G; Buttari, F; Cencioni, MT; Centonze, D; Codecà, C; Fiore, S; Koch, G; Maccarrone, M; Mori, F; Rossi, S | 1 |
| Börner, C; Höllt, V; Kraus, J; Schraven, B; Smida, M | 1 |
| Alsindi, Z; Ambler, Z; Collin, C; Davies, P; Ehler, E; Notcutt, W; Nováková, I; O'Leary, C; Piková, J; Powell, K; Ratcliffe, S; Waberzinek, G; Zapletalova, O | 1 |
| Collin, C; Duncombe, P; Stott, C; Wade, DT | 1 |
| Kmietowicz, Z | 1 |
| Bernardi, G; Buttari, F; Centonze, D; Codecà, C; Fiore, S; Koch, G; Kusayanagi, H; Monteleone, F; Mori, F | 1 |
| Constantinescu, CS; De Ridder, D; Fowler, CJ; Kavia, RB; Stott, CG | 1 |
| Gross, H | 1 |
| Ambler, Z; Cefaro, L; Comi, G; Davies, P; Erdmann, A; Gasperini, C; Klimek, A; Mares, J; Montalban, X; Novakova, I; Novotna, A; Pozzilli, C; Ratcliffe, S; Rossi, P; Stelmasiak, Z; Vachova, M; Zapletalova, O | 1 |
| Haas, J | 1 |
| Di Marzo, V | 1 |
| Clissold, S; Montalban, X; Sastre-Garriga, J; Vila, C | 1 |
| Robson, P | 1 |
| Solaro, C | 1 |
| Oreja-Guevara, C | 2 |
| Wade, D | 1 |
| Gras, A; Slof, J | 1 |
| Notcutt, WG | 1 |
| Barnes, D; Hobart, JC; Mattison, PG; Slade, A; Zajicek, JP | 1 |
| Collin, C; Notcutt, W; Serpell, MG | 1 |
| Constantinescu, CS; Podda, G | 1 |
| Altman, DG; Duncombe, P; Wright, S | 1 |
| Lang, IA; Lu, L; Pearce, H; Roome, C; Shearer, J; Stein, K | 1 |
| Langford, RM; Mares, J; Notcutt, W; Novakova, I; Novotna, A; Ratcliffe, S; Vachova, M | 1 |
| Gramstad, L; Sagabråten, AS | 1 |
| García-Merino, A | 1 |
| Smith, PF | 3 |
| Pertwee, RG | 1 |
| Russo, EB | 1 |
| Blauw, B; Hoogervorst, EL; Killestein, J; Nagelkerken, L; Polman, CH; Reif, M; Smits, M; Uitdehaag, BM | 1 |
| Croxford, JL; Miller, SD | 1 |
| Metz, L; Page, S | 1 |
| Fox, P; Nunn, A; Sanders, H; Thompson, A; Vickery, J; Wright, D; Zajicek, J | 1 |
| Baker, D; Constanti, A; Gibbons, S; Pryce, G; Whalley, BJ; Wilkinson, JD; Williamson, EM | 1 |
| Capellà, D; Duran, M; Laporte, JR | 1 |
| Szendrei, K | 1 |
| Miller, R; Newport, S; Notcutt, W; Phillips, C; Price, M; Sansom, C; Simmons, S | 1 |
| Berg, AT; Sirven, JI | 1 |
| Bach, FW; Jensen, TS; Svendsen, KB | 2 |
| Gattlen, B; Hagen, U; Heinzel-Gutenbrunner, M; Jobin, P; Reif, M; Schnelle, M; Tschopp, F; Vaney, C | 1 |
| Berkley, KJ; Brady, CM; Dalton, C; DasGupta, R; Fowler, CJ; Wiseman, OJ | 1 |
| Bateman, C; House, H; Makela, P; Robson, P; Wade, DT | 1 |
| Berger, T; Bodner, T; Entner, T; Fleischhacker, WW; Kemmler, G; Kurzthaler, I; Wissel, J | 1 |
| Kaminski, E; Katona, S; Sanders, H; Zajicek, J | 1 |
| Sibbald, B | 1 |
| Friede, T; Nurmikko, TJ; Rog, DJ; Young, CA | 1 |
| Adekanmi, O; Freeman, RM; Waterfield, AE; Waterfield, MR; Wright, D; Zajicek, J | 1 |
| Barnes, MP | 1 |
| Collin, C; Davies, P; Mutiboko, IK; Ratcliffe, S | 1 |
| Bari, M; Battistini, L; Bernardi, G; Bernardini, S; Centonze, D; De Chiara, V; Fezza, F; Furlan, R; Maccarrone, M; Martino, G; Prosperetti, C; Rossi, S | 1 |
| Scully, C | 1 |
| Nurmikko, TJ; Rog, DJ; Young, CA | 1 |
| Burket, JA; Connor, JM; Deutsch, SI; Fox, FJ; Murphy, ME; Rosse, RB | 1 |
| Clifford, DB | 1 |
| Illis, LS; Martyn, CN; Thom, J | 1 |
| Schwartz, RH; Voth, EA | 1 |
| di Vadi, PP; Hamann, W | 1 |
| Achiron, A; Biegon, A; Lavie, V; Margalit, R; Miron, S | 1 |
| Gorter, RW; Hoogervorst, EL; Kalkers, NF; Killestein, J; Polman, CH; Reif, M; Staats, PG; Uitdehaag, BM; Van Loenen, AC | 1 |
| Check, WA | 1 |
| Lyman, WD | 1 |
| Andyrsiak, T; Ellison, GW; Fairbanks, L; Myers, LW; Ungerleider, JT | 1 |
61 review(s) available for dronabinol and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Observational Studies as Topic; Plant Extracts | 2021 |
Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity | 2022 |
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Topics: Activities of Daily Living; Adolescent; Adult; Analgesics; Cannabinoids; Cannabis; Chronic Pain; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Neuralgia; Plant Extracts; Quality of Life; Young Adult | 2022 |
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2022 |
Effects of Sativex
Topics: Cannabidiol; Cognition; Double-Blind Method; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
Topics: Cannabidiol; Cannabis; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis | 2023 |
Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
Topics: Adult; Cannabidiol; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient.
Topics: Cancer Pain; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoids; Cannabis; Chronic Pain; Cystitis, Interstitial; Dronabinol; Drug Combinations; Humans; Lower Urinary Tract Symptoms; Male; Medical Marijuana; Multiple Sclerosis; Pain, Procedural; Pelvic Pain; Urinary Incontinence | 2020 |
Cannabis and multiple sclerosis.
Topics: Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Drug Combinations; Humans; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Pain; Urologic Diseases | 2020 |
A Critical Review of the Role of the Cannabinoid Compounds Δ
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Baclofen; Cannabidiol; Clinical Trials as Topic; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Drug Approval; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Multiple Sclerosis; Spinal Cord; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.
Topics: Aged; Anorexia; Antineoplastic Agents; Cancer Pain; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoids; Dizziness; Dose-Response Relationship, Drug; Dronabinol; Humans; Middle Aged; Multiple Sclerosis; Nausea; Neurodegenerative Diseases; Pain; Perceptual Disorders; Randomized Controlled Trials as Topic; Regression Analysis; Self Report; Vomiting | 2021 |
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Topics: Analgesics, Opioid; Cannabidiol; Chronic Pain; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Registries | 2021 |
Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cannabidiol; Cannabinoids; Cannabis; Cartilage Diseases; Cytokines; Diabetes Mellitus, Type 1; Dronabinol; Humans; Immunomodulation; Lupus Erythematosus, Systemic; Mice; Multiple Sclerosis; Th17 Cells | 2021 |
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
Topics: Cannabidiol; Clinical Trials as Topic; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Treatment Outcome | 2017 |
Multiple sclerosis symptoms and spasticity management: new data.
Topics: Cannabidiol; Disease Management; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Oral Sprays | 2017 |
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
Topics: Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Pain; Quality of Life; Randomized Controlled Trials as Topic; Systematic Reviews as Topic | 2018 |
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Topics: Automobile Driving; Cannabidiol; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents | 2018 |
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Medical Marijuana; Multiple Sclerosis; Nervous System Diseases; Treatment Outcome | 2018 |
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Topics: Baclofen; Cannabidiol; Disease Progression; Dronabinol; Drug Combinations; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Nasal Sprays; Plant Extracts; Quality of Life | 2018 |
Dark Classics in Chemical Neuroscience: Δ
Topics: Cannabis; Chronic Pain; Dronabinol; Humans; Medical Marijuana; Multiple Sclerosis; Nausea | 2019 |
[Marihuana and cannobinoids as medicaments].
Topics: Arthritis, Rheumatoid; Cannabidiol; Cannabinoids; Cannabis; Contraindications; Dronabinol; Drug Combinations; Humans; Inflammatory Bowel Diseases; Multiple Sclerosis; Muscle Spasticity; Nausea; Nervous System Diseases; Pain; Plant Extracts; Vomiting | 2012 |
[Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia].
Topics: Analgesics, Non-Narcotic; Anorexia; Cachexia; Dose-Response Relationship, Drug; Dronabinol; Long-Term Care; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Phytotherapy; Plant Extracts; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Treatment Outcome | 2004 |
Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
Topics: Analgesics; Canada; Cannabidiol; Cannabinoids; Clinical Trials as Topic; Dronabinol; Drug Combinations; Drug Evaluation, Preclinical; Humans; Multiple Sclerosis; Neuralgia; Plant Preparations; Randomized Controlled Trials as Topic | 2013 |
Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
Topics: Adult; Aged; Cannabidiol; Dronabinol; Drug Combinations; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Treatment Outcome | 2013 |
THC:CBD spray and MS spasticity symptoms: data from latest studies.
Topics: Affect; Automobile Driving; Cannabidiol; Clinical Trials as Topic; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Parasympatholytics; Plant Extracts; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic | 2014 |
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Topics: Adult; Cannabidiol; Cannabinoid Receptor Agonists; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Severity of Illness Index | 2014 |
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
Topics: Activities of Daily Living; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Outcome Assessment, Health Care; Plant Extracts; Quality of Life | 2014 |
Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Plant Extracts | 2014 |
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Treatment Outcome | 2014 |
Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
Topics: Cannabidiol; Clinical Trials as Topic; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Oral Sprays; Placebo Effect | 2015 |
Medical marijuana for cancer.
Topics: Analgesics, Non-Narcotic; Antiemetics; Canada; Cannabidiol; Clinical Trials as Topic; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Medical Marijuana; Multiple Sclerosis; Neoplasms; Pain; Treatment Outcome; United Kingdom; United States | 2015 |
Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Sleep; Visual Analog Scale | 2015 |
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Treatment Outcome | 2015 |
Advances in the management of MS symptoms: real-life evidence.
Topics: Activities of Daily Living; Cannabidiol; Disease Management; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Product Surveillance, Postmarketing | 2015 |
Advances in the management of MS symptoms: recently proposed clinical management algorithms.
Topics: Algorithms; Cannabidiol; Clinical Trials as Topic; Disease Management; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2015 |
THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
Topics: Accidental Falls; Cannabidiol; Depression; Dronabinol; Drug Combinations; Germany; Humans; Marijuana Abuse; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Plant Extracts; Prospective Studies; Registries; Retrospective Studies; Spain; Switzerland; Treatment Outcome; United Kingdom | 2016 |
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds.
Topics: Analgesics; Cannabidiol; Doping in Sports; Dronabinol; Drug Combinations; Gas Chromatography-Mass Spectrometry; Hair; Humans; Multiple Sclerosis; Plant Extracts; Workplace | 2016 |
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diazepam; Dronabinol; Drug Combinations; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Phenol | 2016 |
Evolution of multiple sclerosis spasticity-associated symptoms: latest data.
Topics: Administration, Oral; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Plant Extracts; Randomized Controlled Trials as Topic | 2016 |
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2017 |
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain Measurement; Plant Extracts; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2010 |
Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Reproducibility of Results; Self Report; Severity of Illness Index | 2011 |
Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
Topics: Animals; Cannabidiol; Disease Models, Animal; Dronabinol; Drug Combinations; Endocannabinoids; Mice; Multiple Sclerosis; Muscle Spasticity; Muscle, Skeletal; Plant Extracts | 2011 |
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Endocannabinoids; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality of Life; Treatment Outcome | 2011 |
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Topics: Administration, Mucosal; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic | 2011 |
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
Topics: Cannabidiol; Cannabinoids; Clinical Trials as Topic; Dronabinol; Drug Combinations; Humans; Marijuana Abuse; Multiple Sclerosis; Plant Extracts; Psychotropic Drugs; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2011 |
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Topics: Cannabidiol; Cannabinoids; Clinical Trials as Topic; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality of Life; Spain | 2012 |
Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
Topics: Cannabidiol; Clinical Trials as Topic; Dronabinol; Drug Combinations; Drug Tolerance; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Psychotropic Drugs | 2012 |
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Topics: Analgesics; Animals; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Treatment Outcome; Urologic Diseases | 2012 |
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Topics: Administration, Sublingual; Cannabidiol; Clinical Trials, Phase III as Topic; Double-Blind Method; Dronabinol; Drug Combinations; Humans; Legislation, Drug; Multicenter Studies as Topic; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Powders; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Retrospective Studies; Spain; Treatment Outcome | 2012 |
Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.
Topics: Bias; Cannabidiol; Clinical Trials, Phase III as Topic; Double-Blind Method; Dronabinol; Drug Combinations; Humans; Linear Models; Marijuana Smoking; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Plant Extracts; Randomized Controlled Trials as Topic; Research Design; Self Report; Severity of Illness Index; Treatment Outcome | 2012 |
What place for ▾ cannabis extract in MS?
Topics: Adult; Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Costs; Drug Interactions; Humans; Meta-Analysis as Topic; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Topics: Anti-Dyskinesia Agents; Attitude of Health Personnel; Attitude to Health; Cannabidiol; Cannabinoid Receptor Agonists; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Costs; Drug Resistance; Germany; Health Care Costs; Humans; Multiple Sclerosis; Muscle Spasticity; Physicians; Plant Extracts; Quality of Life | 2013 |
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
Topics: Anti-Dyskinesia Agents; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Clinical Trials, Phase III as Topic; Cost of Illness; Dronabinol; Drug Combinations; Drug Resistance; Drugs, Investigational; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Practice Patterns, Physicians'; Quality of Life; Randomized Controlled Trials as Topic; Spain; United Kingdom | 2013 |
Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
Topics: Analgesics, Non-Narcotic; Animals; Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Disease Models, Animal; Dronabinol; Fatty Acids, Unsaturated; Humans; Multiple Sclerosis; Muscle Weakness; Pain; Receptors, Cannabinoid; Receptors, Drug; Spasm | 2002 |
Cannabinoids and multiple sclerosis.
Topics: Animals; Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Clinical Trials as Topic; Dronabinol; Humans; Multiple Sclerosis | 2002 |
[News about therapeutic use of Cannabis and endocannabinoid system].
Topics: Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Dronabinol; Endocannabinoids; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Receptors, Cannabinoid | 2004 |
[A novel analgesics made from Cannabis].
Topics: Analgesics; Arachidonic Acids; Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Combinations; Drugs, Investigational; Endocannabinoids; Europe; Humans; Multiple Sclerosis; Pain; Plant Extracts; Polyunsaturated Alkamides | 2004 |
Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Topics: Analgesics; Cannabidiol; Cannabinoids; Dronabinol; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Self Administration; Sleep Wake Disorders | 2006 |
Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.
Topics: Appetite Stimulants; Cannabis; Dronabinol; Glaucoma; Humans; Multiple Sclerosis; Muscle Spasticity; Nausea; Neoplasms | 1997 |
Drugs of abuse and experimental autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Demyelinating Diseases; Disease Models, Animal; Dronabinol; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Female; Immunosuppressive Agents; Lymphocyte Activation; Male; Multiple Sclerosis; Neuritis, Autoimmune, Experimental; Polyradiculoneuropathy; Rats; Rats, Inbred Lew | 1991 |
33 trial(s) available for dronabinol and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Muscle Tonus; Randomized Controlled Trials as Topic; Spasm | 2023 |
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Topics: Adult; Analgesics; Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Myalgia; Oral Sprays; Outcome Assessment, Health Care; Severity of Illness Index | 2020 |
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Gait Analysis; Humans; Multiple Sclerosis; Muscle Spasticity; Walking | 2021 |
The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.
Topics: Adolescent; Adult; Analgesics; Biomechanical Phenomena; Cannabidiol; Clinical Protocols; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neurological Rehabilitation; Oral Sprays; Robotics; Single-Blind Method; Treatment Outcome; Young Adult | 2017 |
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Topics: Adult; Analgesics; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth; Multiple Sclerosis; Muscle Spasticity; Pilot Projects; Prospective Studies; Stomatitis; Taste; Taste Perception; Treatment Outcome | 2018 |
Sativex
Topics: Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Prospective Studies; Treatment Outcome | 2019 |
The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Topics: Adult; Australia; Cannabidiol; Cannabinol; Chromatography, Liquid; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Multiple Sclerosis; Muscle Relaxants, Central; Oral Sprays; Pilot Projects; Plant Extracts; Saliva; Substance Abuse Detection; Tandem Mass Spectrometry | 2014 |
Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.
Topics: Adult; Brain; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Laser-Evoked Potentials; Male; Middle Aged; Multiple Sclerosis; Neuralgia; Pain Management; Pain Measurement; Plant Extracts; Transcranial Magnetic Stimulation | 2016 |
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Topics: Adult; Baclofen; Cannabidiol; Clonidine; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts | 2016 |
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Motor Neurons; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Pyramidal Tracts | 2017 |
Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
Topics: Adult; Arachidonic Acids; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Endocannabinoids; Female; Humans; Lymphocytes; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain; Plant Extracts; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reflex, Stretch; Treatment Outcome; Young Adult | 2009 |
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
Topics: Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Plant Extracts; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
Topics: Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Plant Extracts; Urinary Bladder, Overactive | 2010 |
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
Topics: Adult; Aged; Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2011 |
Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
Topics: Adolescent; Adult; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Muscle Tonus; Pain; Phytotherapy; Plant Extracts; Self Report; Severity of Illness Index; Sleep; Walking | 2012 |
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Electrocardiography; Female; Humans; Longitudinal Studies; Male; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Pain Measurement; Phytotherapy; Plant Extracts; Sleep | 2013 |
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Topics: Administration, Mucosal; Administration, Oral; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Cannabidiol; Double-Blind Method; Dronabinol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Neuralgia; Pain Measurement; Treatment Outcome | 2013 |
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Topics: Cannabidiol; Cannabinoids; Dronabinol; Female; Humans; Locomotion; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Outcome Assessment, Health Care; Physical Examination; Placebos; Secondary Prevention; Treatment Outcome; United Kingdom; Walking | 2003 |
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Non-Narcotic; Cannabidiol; Chronic Disease; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Pain Measurement; Patient Selection; Sleep; Treatment Outcome | 2004 |
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Cannabinoids; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Treatment Outcome | 2004 |
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Administration, Oral; Cannabidiol; Capsules; Cross-Over Studies; Double-Blind Method; Dronabinol; Humans; Movement; Multiple Sclerosis; Muscle Spasticity; Sleep | 2004 |
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
Topics: Aerosols; Cannabidiol; Cannabis; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Humans; Mouth Mucosa; Multiple Sclerosis; Muscle Spasticity; Pain; Pain Measurement; Plant Extracts; Tremor; Urinary Bladder Diseases | 2004 |
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series.
Topics: Adult; Aged; Antiemetics; Attention; Automobile Driving; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Memory, Short-Term; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain; Prospective Studies; Psychomotor Performance; Reaction Time | 2005 |
Cannabinoid influence on cytokine profile in multiple sclerosis.
Topics: C-Reactive Protein; Cannabinoids; Cannabis; Cells, Cultured; Cytokines; Double-Blind Method; Dronabinol; Female; Humans; Immunologic Factors; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Multiple Sclerosis; Phytotherapy; Plant Oils | 2005 |
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication].
Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Pain Measurement; Treatment Outcome | 2005 |
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Topics: Administration, Oral; Adult; Aged; Analgesics; Cannabinoids; Central Nervous System; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Humans; Male; Memory Disorders; Middle Aged; Multiple Sclerosis; Pain Measurement; Pain Threshold; Pain, Intractable; Phytotherapy; Placebos; Plant Preparations; Sleep Wake Disorders; Treatment Outcome | 2005 |
The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
Topics: Analgesics, Non-Narcotic; Cannabidiol; Cannabinoids; Comorbidity; Dronabinol; Female; Humans; Middle Aged; Multiple Sclerosis; Quality of Life; Urinary Incontinence, Urge; Urination; Urodynamics | 2006 |
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
Topics: Administration, Oral; Adult; Cannabidiol; Cannabinoids; Central Nervous System; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Placebos; Plant Extracts; Treatment Outcome | 2007 |
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aerosols; Analgesics, Opioid; Cannabidiol; Central Nervous System Diseases; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Pain; Plant Extracts | 2007 |
Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
Topics: Adult; Cannabis; Dronabinol; Female; Hallucinogens; Humans; Male; Marijuana Abuse; Multiple Sclerosis; Nocturnal Paroxysmal Dystonia; Phytotherapy; Tics | 2008 |
Tetrahydrocannabinol for tremor in multiple sclerosis.
Topics: Adult; Ataxia; Clinical Trials as Topic; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Placebos; Tremor | 1983 |
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Topics: Administration, Oral; Cannabinoids; Cannabis; Cross-Over Studies; Double-Blind Method; Dronabinol; Health Status; Humans; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Muscle Tonus; Pain Measurement; Plant Extracts; Sample Size; Treatment Outcome | 2002 |
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Disability Evaluation; Dronabinol; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Random Allocation | 1987 |
102 other study(ies) available for dronabinol and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
Topics: Cannabidiol; Central Nervous System Diseases; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Cramp; Muscle Spasticity; Pain; Spasm; Treatment Outcome | 2022 |
Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity.
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Humans; Male; Multiple Sclerosis; Muscle Spasticity | 2023 |
Cannabis-based products and multiple sclerosis-related pain: The role of routes of administration.
Topics: Cannabis; Dronabinol; Humans; Multiple Sclerosis; Pain | 2023 |
Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Topics: Animals; Anti-Inflammatory Agents; Brain; Cannabidiol; Cells, Cultured; Cytokines; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Leukocytes, Mononuclear; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Multiple Sclerosis; Signal Transduction; Spinal Cord; Spleen | 2019 |
The effects of chronic Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) use on cerebral glucose metabolism in multiple sclerosis: a pilot study.
Topics: Adult; Aged; Cannabidiol; Cerebral Cortex; Dronabinol; Female; Glucose; Humans; Male; Middle Aged; Multiple Sclerosis; Pilot Projects | 2020 |
Predictors of Nabiximols (Sativex
Topics: Adult; Analgesics, Non-Narcotic; Cannabidiol; Cognitive Dysfunction; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Patient Compliance; Patient Dropouts; Retrospective Studies; Severity of Illness Index | 2020 |
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis.
Topics: Adult; Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Quality of Life; Quality-Adjusted Life Years | 2020 |
Cannabis-based medicinal products: summary of NICE guidance.
Topics: Antiemetics; Antineoplastic Agents; Cannabidiol; Cannabinoid Receptor Agonists; Chronic Pain; Decision Making, Shared; Dronabinol; Drug and Narcotic Control; Drug Resistant Epilepsy; Epilepsies, Myoclonic; Humans; Lennox Gastaut Syndrome; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Nausea; Needs Assessment; Physicians, Primary Care; Practice Guidelines as Topic; Specialization; United Kingdom; Vomiting | 2020 |
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Italy; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Retrospective Studies | 2020 |
Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Gait; Humans; Multiple Sclerosis; Robotic Surgical Procedures | 2020 |
Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
Topics: Adult; Aged; Cannabidiol; Cognition; Cognition Disorders; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuropsychological Tests; Oral Sprays; Parasympatholytics; Pilot Projects; Prospective Studies; Single-Blind Method; Young Adult | 2020 |
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Patient Compliance; Prospective Studies; Time Factors; Treatment Outcome; Withholding Treatment | 2020 |
Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
Topics: Cannabidiol; Cannabis; Dronabinol; Humans; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Oils | 2021 |
Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Goals; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pilot Projects; Plant Extracts; Proof of Concept Study; Prospective Studies; Quality of Life; Treatment Outcome | 2021 |
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
Topics: Botulinum Toxins; Botulinum Toxins, Type A; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Retrospective Studies; Spasm; Treatment Outcome | 2021 |
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
Topics: Belgium; Cannabidiol; Cannabinoids; Dronabinol; Drug Administration Schedule; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Patient Reported Outcome Measures; Plant Extracts; Quality of Life; Retrospective Studies; Severity of Illness Index | 2021 |
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
Topics: Adult; Aged; Aged, 80 and over; Cannabidiol; Cost Sharing; Dronabinol; Drug Approval; Drug Combinations; Drug Costs; Drug Industry; Female; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Multivariate Analysis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Proportional Hazards Models; Registries; Regression Analysis; Severity of Illness Index; Young Adult | 2017 |
THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
Topics: Administration, Mucosal; Administration, Oral; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Pilot Projects; Prospective Studies; Treatment Outcome; Urinary Bladder, Overactive | 2018 |
Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Topics: Antiemetics; Antineoplastic Agents; Cannabidiol; Cannabinoid Receptor Agonists; Chronic Pain; Dronabinol; Drug Approval; Drug Combinations; Europe; Germany; Humans; Israel; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Nausea; Pain Management; Palliative Care; Societies, Medical; Surveys and Questionnaires; Vomiting | 2018 |
What's new in multiple sclerosis spasticity research? Poster session highlights.
Topics: Cannabidiol; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Oral Sprays | 2017 |
Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.
Topics: Adult; Cannabidiol; Down-Regulation; Dronabinol; Drug Combinations; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Sclerosis | 2018 |
Balance worsening associated with nabiximols in multiple sclerosis.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Postural Balance; Psychomotor Performance; Stroop Test | 2019 |
Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited.
Topics: Cannabidiol; Cannabinoids; Down-Regulation; Dronabinol; Drug Combinations; Humans; Immunomodulation; Multiple Sclerosis | 2018 |
Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Topics: Activities of Daily Living; Adult; Cannabidiol; Dronabinol; Drug Combinations; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome | 2018 |
Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
Topics: Administration, Mucosal; Cannabidiol; Cannabinoid Receptor Modulators; Congresses as Topic; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Randomized Controlled Trials as Topic; Societies, Medical | 2019 |
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
Topics: Administration, Mucosal; Affect; Cannabidiol; Cannabinoid Receptor Modulators; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic | 2019 |
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Topics: Administration, Mucosal; Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Drug Approval; Drug Combinations; Humans; Italy; Multiple Sclerosis; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Pragmatic Clinical Trials as Topic; Registries | 2019 |
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Topics: Animals; Cannabidiol; Cannabinoids; Cannabis; Cytokines; Disease Models, Animal; Dronabinol; Dysbiosis; Encephalomyelitis, Autoimmune, Experimental; Female; Gastrointestinal Microbiome; Inflammation; Interferon-gamma; Interleukin-17; Mice; Mice, Inbred C57BL; Multiple Sclerosis; RNA, Ribosomal, 16S | 2019 |
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Topics: Cannabidiol; Combined Modality Therapy; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Physical Therapy Modalities; Withholding Treatment | 2019 |
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Cannabidiol; Dronabinol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain; Retrospective Studies; Treatment Outcome | 2014 |
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Topics: Adult; Cannabidiol; Disability Evaluation; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Retrospective Studies; Treatment Outcome | 2014 |
Overview of MS spasticity.
Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Practice Guidelines as Topic | 2014 |
Who benefits most from THC:CBD spray? Learning from clinical experience.
Topics: Activities of Daily Living; Adult; Aged; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Parasympatholytics; Plant Extracts; Quality of Life; Severity of Illness Index; Spinal Cord; Treatment Outcome | 2014 |
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Topics: Adult; Aged; Cannabidiol; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Plant Extracts; Prospective Studies; Severity of Illness Index; Sleep; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
[Cannabis - medicinal use].
Topics: Administration, Oral; Affect; Cannabidiol; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Germany; Humans; Marijuana Abuse; Marijuana Smoking; Medical Marijuana; Multiple Sclerosis; Pain, Intractable; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Receptors, Cannabinoid; Risk Factors; Wasting Syndrome | 2014 |
[Therapeutic use of cannabis derivatives].
Topics: Antiemetics; Cannabidiol; Dronabinol; Drug Combinations; Fibromyalgia; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Plant Extracts | 2014 |
Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.
Topics: Adult; Aged; Aged, 80 and over; Cannabidiol; Cannabis; Chronic Pain; Cross-Sectional Studies; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Netherlands; Patient Satisfaction; Phytotherapy; Plant Preparations; Psychometrics; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Topics: Adult; Aged; Analgesics; Cannabidiol; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Patient Satisfaction; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis.
Topics: Administration, Mucosal; Aerosols; Cannabidiol; Dronabinol; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Packaging; Drug Storage; Evidence-Based Medicine; Humans; Multiple Sclerosis; Neuromuscular Agents; Treatment Outcome | 2014 |
What is a crossover trial?
Topics: Cannabinoid Receptor Agonists; Cross-Over Studies; Dronabinol; Humans; Multiple Sclerosis; Neuralgia; Randomized Controlled Trials as Topic; Research Design | 2014 |
Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Topics: Adult; Automobile Driving; Cannabidiol; Dronabinol; Drug Combinations; Female; Germany; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pilot Projects; Plant Extracts | 2015 |
Should patient groups be more transparent about their funding?
Topics: Analgesics; Cannabidiol; Capital Financing; Charities; Dronabinol; Drug Combinations; Drug Industry; Humans; Multiple Sclerosis; Self-Help Groups; United Kingdom | 2014 |
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
Topics: Animals; Cannabidiol; Dronabinol; Drug Combinations; Endocannabinoids; Humans; Motor Cortex; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Muscle, Skeletal; Neural Pathways; Plant Extracts; Spinal Cord | 2014 |
Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Topics: Affect; Cannabidiol; Clinical Trials, Phase III as Topic; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Plant Extracts; Randomized Controlled Trials as Topic | 2014 |
Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
Topics: Activities of Daily Living; Cannabidiol; Cost of Illness; Dronabinol; Drug Combinations; Europe; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Plant Extracts; Quality of Life | 2014 |
Advances in the management of MS spasticity: recent observational studies.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Germany; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Plant Extracts; Registries; Spain; United Kingdom | 2014 |
Transparency of funding of patient groups is mandatory but is not enough.
Topics: Analgesics; Cannabidiol; Capital Financing; Charities; Dronabinol; Drug Industry; Humans; Multiple Sclerosis | 2014 |
Who will support independent patient groups?
Topics: Analgesics; Cannabidiol; Capital Financing; Charities; Dronabinol; Drug Industry; Humans; Multiple Sclerosis | 2014 |
Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
Topics: Cannabidiol; Cannabinoid Receptor Agonists; Cerebral Cortex; Dronabinol; Drug Combinations; Evoked Potentials, Motor; Humans; Multiple Sclerosis; Muscle Spasticity; Neural Inhibition; Plant Extracts; Pyramidal Tracts; Sensorimotor Cortex; Transcranial Magnetic Stimulation | 2015 |
[Assessment of the effectiveness and safety of Sativex® in compassionate use].
Topics: Adult; Aged; Cannabidiol; Compassionate Use Trials; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Treatment Outcome | 2015 |
Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
Topics: Cannabidiol; Cost of Illness; Cost-Benefit Analysis; Delivery of Health Care; Dronabinol; Drug Combinations; Humans; Italy; Markov Chains; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality-Adjusted Life Years | 2015 |
[A breakthrough for the treatment of spasticity in multiple sclerosis].
Topics: Cannabidiol; Cannabis; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts | 2015 |
A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
Topics: Animals; Cannabidiol; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Mice; Mice, Inbred Strains; Multiple Sclerosis; Plant Extracts; Theilovirus | 2015 |
Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!
Topics: Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Middle Aged; Multiple Sclerosis; Self-Injurious Behavior; Suicidal Ideation | 2015 |
Walking improvements with nabiximols in patients with multiple sclerosis.
Topics: Adult; Biomechanical Phenomena; Cannabidiol; Dronabinol; Drug Combinations; Female; Gait Disorders, Neurologic; Humans; Male; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care; Severity of Illness Index; Walking | 2015 |
The cannabis experiment.
Topics: Adolescent; Appetite; Biomedical Research; Cannabis; Child; Colorado; Confounding Factors, Epidemiologic; Dronabinol; Humans; Marijuana Abuse; Marijuana Smoking; Medical Marijuana; Multiple Sclerosis; Netherlands; New Zealand; Prevalence; Schizophrenia; Seizures; Sweden; Young Adult | 2015 |
A potted history.
Topics: Animals; Canada; Cannabidiol; Cannabinol; Cannabis; China; Dronabinol; Drug and Narcotic Control; Drug Approval; Drug Combinations; Endocannabinoids; Herbal Medicine; History, 16th Century; History, 17th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; History, Medieval; Humans; Medical Marijuana; Multiple Sclerosis; New Orleans; Phytotherapy; Plant Extracts; Plants, Medicinal; Receptors, Cannabinoid | 2015 |
Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Topics: Adult; Cannabidiol; Cohort Studies; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Severity of Illness Index; Treatment Outcome | 2016 |
Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Prospective Studies | 2015 |
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Topics: Adult; Aged; Cannabidiol; Cohort Studies; Dronabinol; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Time Factors; Treatment Outcome; Young Adult | 2016 |
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Topics: Adult; Cannabidiol; Cost Savings; Cost-Benefit Analysis; Dronabinol; Hospitalization; Humans; Markov Chains; Models, Economic; Multiple Sclerosis; Muscle Spasticity; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Wales | 2016 |
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxylic Acids; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Germany; Humans; Italy; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Plant Extracts; Pregabalin; Prospective Studies; Treatment Outcome | 2016 |
Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
Topics: Adult; Cannabidiol; Data Collection; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Plant Extracts; Prospective Studies; Registries; Treatment Outcome | 2016 |
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Topics: Administration, Oral; Adult; Aged; Analgesics; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Muscle Spasticity; Reflex, Stretch; Treatment Outcome | 2016 |
The therapeutic use of cannabinoids: Forensic aspects.
Topics: Administration, Inhalation; Analgesics, Non-Narcotic; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Female; Forensic Toxicology; Humans; Male; Middle Aged; Multiple Sclerosis; Pain, Intractable | 2016 |
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Topics: Administration, Oral; Cannabidiol; Dronabinol; Drug Combinations; Humans; Italy; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Safety | 2016 |
Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Follow-Up Studies; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2016 |
The use of medical-grade cannabis in patients non-responders to Nabiximols.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Retrospective Studies; Treatment Outcome | 2016 |
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Topics: Activities of Daily Living; Adult; Baclofen; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Plant Extracts; Prospective Studies; Quality of Life | 2016 |
Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Topics: Adult; Aged; Cannabidiol; Cannabinoid Receptor Modulators; Disability Evaluation; Dronabinol; Drug Combinations; Evoked Potentials, Motor; Female; Follow-Up Studies; H-Reflex; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Nasal Sprays; Neuromuscular Agents; Oral Sprays; Plant Extracts; Severity of Illness Index; Treatment Outcome | 2016 |
Country breakout session highlights.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Europe; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Muscle Spasticity | 2016 |
What is new in multiple sclerosis spasticity research? Poster session highlights.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity | 2016 |
[Cannabinoids in medicine].
Topics: Adenocarcinoma; Analgesics; Analgesics, Opioid; Dronabinol; Drug Therapy, Combination; Female; Humans; Middle Aged; Multiple Sclerosis; Pain, Intractable; Palliative Care; Quality of Life; Uterine Neoplasms | 2008 |
Willingness to pay for a treatment for pain in multiple sclerosis.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aerosols; Aged; Aged, 80 and over; Analgesics, Opioid; Attitude to Health; Cannabidiol; Cost-Benefit Analysis; Decision Making; Dronabinol; Drug Combinations; Fees and Charges; Female; Humans; Insurance, Health; Interviews as Topic; Male; Middle Aged; Multiple Sclerosis; Pain; Patient Satisfaction; Plant Extracts; Surveys and Questionnaires | 2009 |
Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.
Topics: Arachidonic Acids; Cannabinoids; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dronabinol; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Indoles; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Morpholines; Multiple Sclerosis; Phosphorylation; Protein-Tyrosine Kinases; Psychotropic Drugs; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; T-Lymphocytes | 2009 |
Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
Topics: Administration, Oral; Administration, Sublingual; Cannabinoids; Cannabis; Dronabinol; Humans; Marijuana Smoking; Meta-Analysis as Topic; Multiple Sclerosis; Neuralgia; Pain; Phytotherapy; Plant Preparations; Randomized Controlled Trials as Topic | 2009 |
Cannabis based drug is licensed for spasticity in patients with MS.
Topics: Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Approval; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts | 2010 |
Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans.
Topics: Adult; Animals; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evoked Potentials, Motor; Female; Humans; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Multiple Sclerosis; Neuronal Plasticity; Plant Extracts; Theta Rhythm; Transcranial Magnetic Stimulation | 2009 |
[Cannabis medicinal drugs. "Psychedelics" by prescription?].
Topics: Cannabidiol; Cannabis; Dronabinol; Drug Approval; Drug Combinations; Germany; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Palliative Care; Phytotherapy; Plant Extracts; Psychoses, Substance-Induced | 2010 |
Evaluate symptomatic therapy in MS: can clinical trials be fine-tuned?
Topics: Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2011 |
Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Topics: Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Costs; Drug Resistance; Germany; Humans; Markov Chains; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality-Adjusted Life Years; Severity of Illness Index; Spain | 2012 |
A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cannabidiol; Caregivers; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Off-Label Use; Phytotherapy; Plant Extracts; Practice Patterns, Physicians'; Sleep; Surveys and Questionnaires; United Kingdom | 2013 |
Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
Topics: Administration, Mucosal; Administration, Oral; Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Markov Chains; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Plant Extracts; Quality-Adjusted Life Years; Severity of Illness Index; United Kingdom | 2012 |
[Cannabis medicines in Norway--the basis for approval].
Topics: Cannabidiol; Dronabinol; Drug Approval; Drug Combinations; Drug Therapy, Combination; Humans; Multiple Sclerosis; Muscle Spasticity; Norway; Oral Sprays; Plant Extracts | 2012 |
Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.
Topics: Anti-Dyskinesia Agents; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Dronabinol; Drug Combinations; Drugs, Investigational; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts | 2013 |
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Topics: Administration, Oral; Affect; Appetite; Cannabidiol; Cannabinoids; Cannabis; Clinical Trials, Phase III as Topic; Double-Blind Method; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Plant Extracts; Reflex, Abnormal; Safety; Sleep; Switzerland; Treatment Outcome; United Kingdom | 2003 |
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Cannabinoids; Cannabis; Confidence Intervals; Cross-Over Studies; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Phytotherapy; Plant Extracts | 2003 |
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.
Topics: Animals; Benzoxazines; Brain; Cardiovirus Infections; Cytokines; Disease Models, Animal; Dronabinol; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Morpholines; Multiple Sclerosis; Myelin Proteolipid Protein; Naphthalenes; Peptide Fragments; RNA, Messenger; Theilovirus; Viral Load | 2003 |
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
Topics: Administration, Oral; Cannabidiol; Cannabinoids; Double-Blind Method; Dronabinol; Drug and Narcotic Control; Humans; Multicenter Studies as Topic; Multiple Sclerosis; Muscle Spasticity; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2003 |
Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?
Topics: Animals; Anticonvulsants; Brain; Cannabis; Chromatography, High Pressure Liquid; Disease Models, Animal; Dronabinol; Epilepsy; Membrane Potentials; Mice; Multiple Sclerosis; Phytotherapy; Plant Preparations; Rats | 2003 |
Marijuana as a treatment for epilepsy and multiple sclerosis? A "grass roots" movement.
Topics: Animals; Canada; Cannabis; Dronabinol; Drug and Narcotic Control; Drug Utilization; Epilepsy; Humans; Kindling, Neurologic; Multiple Sclerosis; Phytotherapy; Plant Preparations; Public Opinion; United States | 2004 |
Medicinal cannabis extracts for the treatment of multiple sclerosis.
Topics: Animals; Cannabis; Chronic Disease; Clinical Trials, Phase III as Topic; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic | 2004 |
GW-1000. GW Pharmaceuticals.
Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Canada; Cannabidiol; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dronabinol; Drug Approval; Drug Combinations; Drug Evaluation, Preclinical; Drug Industry; Humans; Hyperalgesia; Investigational New Drug Application; Mice; Molecular Structure; Multiple Sclerosis; Patents as Topic; Peripheral Nervous System Diseases; Phytotherapy; Plant Extracts; Plant Preparations; Randomized Controlled Trials as Topic; Spinal Cord Injuries; Structure-Activity Relationship | 2004 |
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
Topics: Adult; Cannabidiol; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Follow-Up Studies; Humans; Medical Records; Middle Aged; Multiple Sclerosis; Pilot Projects; Plant Extracts; Sensation; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Incontinence; Urination; Urodynamics | 2004 |
Conditional okay for cannabis prescription drug.
Topics: Canada; Cannabidiol; Cannabis; Dronabinol; Drug Approval; Drug Combinations; Humans; Multiple Sclerosis; Neuralgia; Phytotherapy; Plant Extracts | 2005 |
Sativex for the management of multiple sclerosis symptoms.
Topics: Administration, Oral; Administration, Sublingual; Aerosols; Analgesics; Canada; Cannabidiol; Dronabinol; Drug Approval; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Tremor; United Kingdom | 2005 |
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
Topics: Acute Disease; Adult; Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Corpus Striatum; Disease Models, Animal; Dronabinol; Electrophysiology; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Female; Glycerides; Humans; Lymphocytes; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroprotective Agents; Patch-Clamp Techniques; Polyunsaturated Alkamides; Synaptic Transmission; Tissue Culture Techniques | 2007 |
Cannabis; adverse effects from an oromucosal spray.
Topics: Administration, Oral; Adult; Aerosols; Aged; Burns, Chemical; Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Pain; Phytotherapy; Plant Extracts | 2007 |
Nabilone in the treatment of multiple sclerosis.
Topics: Dronabinol; Humans; Male; Middle Aged; Multiple Sclerosis | 1995 |
Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors.
Topics: Analgesics; Dronabinol; Humans; Multiple Sclerosis; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Receptors, Opioid | 1999 |
Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.
Topics: Acute Disease; Animals; Brain; Dose-Response Relationship, Drug; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intraperitoneal; Injections, Intravenous; Multiple Sclerosis; Neuroprotective Agents; Rats; Rats, Inbred Lew; Recurrence; Spinal Cord; Time Factors; Treatment Outcome | 2000 |
Marijuana may lessen spasticity of MS.
Topics: Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity | 1979 |